NMPA accepts clinical trial application for monkeypox vaccine
chinadaily.com.cn |
Updated: 2023-07-14 19:44
Share
Share - WeChat
The National Medical Products Administration (NMPA) has, on Thursday, officially accepted the clinical trial application for the replication-deficient monkeypox vaccine developed by China National Pharmaceutical Group Corporation (Sinopharm) Beijing Institute of Biological Products.
- Unlocking Shanghai's next wave: Capital, data and talent in flow
- Visually impaired runners enjoy outdoor running in Shanghai
- Xi's discourses on work related to women, children, families published in more foreign languages
- Work on Pearl River double-deck bridge progressing smoothly
- China's superconducting quantum computer ready for commercial use
- Guangzhou Customs releases new measures for efficient clearance during Canton Fair
